Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group will consume ground camelina powder in two 30g sachets daily for 2 months (8 weeks) with food (soup, salad, drinks, yogurt, and other foods) in two times, lunch
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: The age range of 30-55 years, 25=BMI<35 and no weight changes in the past 3 months, having at least 6 months history of diabetes, no insulin treatment and use of blood sugar lowering drugs, no use of some drugs such as glucocorticoids, non-steroidal anti-inflammatory drugs, not receiving omega-3 oils in the last 3 months, Keeping the same physical activities and diet constant during the study and willingness to cooperate during the study
Exclusion criteria
Exclusion criteria: smoking, alcohol or cigarette consumption, hormone therapy, long-term use of drugs, use of glucocorticoid drugs, laxatives, anti-obesity drugs, multivitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics, receiving antioxidant supplements at least three months ago From the beginning of the study, use of nutritional supplements, pregnancy, breastfeeding, history of taking a weight loss diet in the last 6 months or a special diet, use of insulin, intestinal diseases such as intestinal inflammation, intestinal cancer, and digestive problems, suffering from thyroid disorders, Renal, hepatic, pulmonary, anemia (Hb<13g/dl), cardiovascular diseases, infectious diseases, malignancies and cancers treated with radiotherapy, cognitive disorders during the study, being athletes or having heavy physical activity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LPS endotoxin. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Cortisol. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Tryptophan. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Kynurenine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Adrenocorticotropic hormone. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Brain-derived neurotrophic factor. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Lipid profile. Timepoint: At baseline and and two months after the start of the study. Method of measurement: Kit.;Inflammatory and anti-inflammatory indicators (including tumor necrosis factor (TNF), high-sensitivity C-reactive protein (hs-CRP), and interleukins 4, 6, 10, 18). Timepoint: At baseline and and two months after the start of the study. Method of measurement: Kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI). Timepoint: At baseline and two months after baseline. Method of measurement: Scale-Meter.;Energy intake, Daily macronutrient intake (carbohydrate, protein, fat). Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;General Health , Sleep quality, Depression, Anxiety and Stress, Appetite, constipation, household food security, sports activity. Timepoint: At baseline and two months after baseline. Method of measurement: questionnaire.;Blood pressure. Timepoint: At baseline and two months after baseline. Method of measurement: manometer.;Body fat percentage, FAT FREE MASS. Timepoint: At baseline and two months after baseline. Method of measurement: body composition.;Total antioxidant capacity. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Malondialdehyde. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;HbA1c. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Fasting glucose. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Fasting insulin. Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Fructosamine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Pentosidine. Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Total oxidant status (TOS). Timepoint: At baseline and two months after start of the study. Method of measurement: kit.;Carboxymethyl lysine (CML). Timepoint: At baseline and two months after start of the study. Method of measurement: enzyme-linked immunosorbent assay (ELISA) kit.;Soluble receptor for advanced glycation end-products. Timepoint: At baseline and two months after start of the study. Method of measurement: en | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvin Dehghan
Tabriz University of Medical Sciences
Outcome results
None listed